Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2608288 | 0.91 | TSHR (0.44) | TSHRMAPTTHRBLMNAALDH1A1 | |
| SCHEMBL16309307 | 0.86 | THRB (0.48) | TSHRTHRBALDH1A1MEN1KMT2A | |
| SCHEMBL10081661 | 0.85 | THRB (0.42) | TSHRTHRBLMNAALDH1A1HTT | |
| SCHEMBL2608279 | 0.82 | THRB (0.49) | TSHRMAPTTHRBLMNAALDH1A1 | |
| SCHEMBL12259945 | 0.81 | TSHR (0.50) | TSHRMAPTTHRBLMNAALDH1A1 | |
| SCHEMBL4917590 | 0.81 | THRB (0.47) | TSHRTHRBALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL2608292 | 0.81 | MAPT (0.41) | TSHRMAPTLMNAALDH1A1EPHX2 | |
| SCHEMBL18649978 | 0.80 | SMN1; SMN2 (0.47) | TSHRMAPTTHRBLMNAALDH1A1 | |
| SCHEMBL16425945 | 0.80 | THRB (0.47) | TSHRMAPTTHRBALDH1A1EPHX2 | |
| SCHEMBL18039471 | 0.80 | THRB (0.43) | TSHRTHRBALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345180-B2 | Display medium for assessment and method for manufacturing same | ZEON CORPORATION (JP) | 2022-05-31 | — | — | US | disclosed |
| US-20190184732-A1 | DISPLAY MEDIUM FOR ASSESSMENT AND METHOD FOR MANUFACTURING SAME | ZEON CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| US-8158021-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, liquid crystalline polymer, and optical anisotropic article | ZEON CORPORATION (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20110140041-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUNDS, POLYMERIZABLE LIQUID CRYSTAL COMPOSITIONS, LIQUID CRYSTALLINE POLYMERS AND OPTICALLY ANISOTROPIC MATERIALS | ZEON CORPORATION (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20100258764-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE | ZEON CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110140041-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUNDS, POLYMERIZABLE LIQUID CRYSTAL COMPOSITIONS, LIQUID CRYSTALLINE POLYMERS AND OPTICALLY ANISOTROPIC MATERIALS | CCNB1, CCNT1, CCNB2 | TSHR 4683/4885MAPT 303/4885THRB 4128/4885 |
| US-20100258764-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE | LEO1, ZYX, CCNT1 | TSHR 4760/4885MAPT 252/4885THRB 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.